Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pevonedistat with Azacitidine vs Azacitidine in Relapsed/Refractory AML
NCT03745352Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- May 2019
- Primary completion
- Aug 2021
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of pevonedistat in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Planned start May 2019; status: withdrawn.
02
Drugs
pevonedistat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03745352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03745352.